Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track REVB with free AI briefings, catalyst countdowns, and dilution alerts.

REVB · REVELATION BIOSCIENCES, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9.1M Cash on Hand
11.1mo Cash Runway
Follow REVB by email Get an email when REVB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about REVB, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Intravenous Gemini Renal Insufficiency, Chronic Phase 1/2 · NCT06863467 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

REVB holds $9.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 11.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when REVB files for a raise →

👥 Who Owns REVB

Insiders 100% Institutions (13 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
SABBY MANAGEMENT, LLC 5%+ holder (13G) 605,702 88.63% 2025-12-31
James Rolke
Chief Executive Officer, Director
Insider 422,814 61.87% 2026-08-17
Chester Stanley III Zygmont
Chief Financial Officer
Insider 300,138 43.92% 2026-08-17
Jess Roper
Director
Insider 44,839 6.56% 2026-08-17
Jennifer Carver
Director
Insider 44,769 6.55% 2026-08-17
Lakhmir S Chawla
Director
Insider 44,169 6.46% 2026-08-17
George F Tidmarsh
Director
Insider 268 0.04% 2025-02-11

Share count 683,442 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full REVB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REVB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.